Riccardo Tisci Reveals Pre-Collection

Riccardo Tisci reveals a Burberry pre-collection for Fall/Winter 2019. Touching on streetwear and military chic, Riccardo shifts his attention to manifesting codes. A distinct focus on archive prints, house colors, and classic outerwear. Riccardo said: 'I wanted this collection to be a continuation of the story I began to tell in September.'
Riccardo elaborates on animal motifs. Gorilla faces gaze at you from black t-shirts. Leopard collars on Dalmatian print car coats. Leather bridle straps, an homage to the Burberry knight-on-horseback logo, embellish trench coats and suit jackets. A faux mélange shearling coat bows to the new Burberry anti-fur code.
The new TB monogram, which Riccardo worked on with Peter Saville, is abundant. Translated into dark green camouflage for a hoodie, shorts, and a cape. In finespun restatements on scarves, satin skirts, and silk blouses. The intertwined TB pops as a big logo on an orange puffer vest, and a wispy TB motif drifts across men’s shirts and suits.
Riccardo said: 'I wanted to celebrate the beauty, heritage, and legacy that I discovered when I first arrived at Burberry. B Classic is an edit that I’ve curated to honor the icons of the House – pieces like the trench coat, the quilted jacket, the car coat, the kilt – which sits at the heart of the SS19 pre-collection designed by the fantastic Burberry design team.'

Comments

Post a Comment

Popular posts from this blog

Pepsi Buys Rockstar

Pepsi buys Rockstar .     P epsiCo buys Rockstar Energy Beverages for $3.85 billion.     Founded in 2001, Rockstar is drinks designed for people leading an active lifestyle. Available in 20 flavors at convenience and grocery stores in 30 countries. Distributed by PepsiCo in North America since 2009. Supporting the Rockstar lifestyle across the globe through action sports, motorsports, and live music. Pepsi's energy portfolio also includes Kickstart , GameFuel, and Amp Energy.     The deal reflects the shift from reliance on sales of sugary, fizzy drinks toward options ranging from tea and coffee to still and sparkling water varieties, which appeal to health-conscious and younger consumers. Neither PepsiCo nor Coca-Cola owns a major brand in the energy drinks category, which is forecast to grow to more than $80 billion over the next five years and is now dominated by Red Bull.     2 00 countries and territories around the world enjoy ...
Read more

Compass Buys Marucci

Compass buys Marucci.     Compass Diversified Holdings buys Marucci Sports for $200 million.     Marucci Sports was founded in 2009 by Kurt Ainsworth, a retired pitcher for the San Francisco Giants and Baltimore Orioles, Joe Lawrence, a former second baseman for the Toronto Blue Jays, and Reed Dickens, a former White House Assistant Press Secretary under George W. Bush.     Marucci ’s first buy was Marucci Bat Company, launched out of a backyard shed in 2004. Ainsworth then led the buyout of an Amish-run Pennsylvania wood mill in 2008. This solidified Marucci's superior wood supply, and it still supplies all Marucci's wood today. In 2017 Marucci bought Victus , a baseball equipment maker known for its edgy designs and big attitude.     With vertically cohesive wood bat production, a global supplier group, and a client base of MVPs and World Series winners, Marucci and Victus are the top two bats among Big League players. T...
Read more

Gilead Buys Forty Seven

Gilead buys Forty Seven.     Gilead Sciences buys Forty Seven for $4.9 billion.     Forty Seven is a clinical-stage immuno-oncology firm developing therapies targeting cancer immune evasion pathways and specific cell targeting approaches based on tech licensed from Stanford. Forty Seven’s lead program, magrolimab , is a monoclonal antibody against the CD47 receptor, a ‘don’t eat me’ signal that cancer cells commandeer to avoid being ingested by macrophages. Evaluated ant ibodies are in many clinical studies of patients with myelodysplastic syndrome, acute myeloid leukemia, non-Hodgkin lymphoma, and solid tumors. These assets complement the cell therapy franchise Gilead added with its 2017 buy of Kite Pharma .     Beyond magrolimab , Forty Seven is fixing to advance two more compounds into clinical testing. Developing FSI-174, an anti-cKIT antibody, in combination with magrolimab creates a novel, all-antibody conditioning regimen to address ...
Read more